Eli Lilly soared as much as 13.8% on Monday after the pharmaceutical giant revealed its experimental Alzheimer’s drug slowed the rate of decline in trial patients.
The drug, called donanemab, slowed the decline of patients’ ability to think by 32% compared to a placebo, the company said in a press release. If the drug is as effective as the study suggests, donanemab could be the first Alzheimer’s drug to show positive results in a phase 2 trial, according to The New York Times.
The study included 272 patients and studied patients’ declines over two years. The drug’s primary goal was to show a significant slowing of decline in a composite measure of cognition and daily function over 18 months.
Full trial results are set to be presented at a future meeting and submitted for publication in a peer-reviewed clinical journal. Lilly will continue to research the drug’s effectiveness in a 500-patient trial.